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Bartter syndrome Type III is a rare autosomal recessive disorder resulting from an inherited defect in the thick ascending 
limb of the loop of henle of the nephrons in kidney. The typical clinical manifestations in childhood are failure to 
thrive and recurrent episodes of vomiting. Typical laboratory findings which help in the diagnosis are hypokalemic 
metabolic alkalosis, hypomagnesemia and hypercalciuria. We report a case of Type III Bartter syndrome not responding 
to repeated conventional treatment of failure to thrive.
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INTRODUCTION 
Bartter Syndrome (BS) is a group of disorders 
characterized by hypokalemic metabolic alkalosis with 
hypercalciuria and salt wasting. The condition is named 
after Dr. Frederic Bartter, who along with Dr. Pacita 
Pronove, first described it in 1960.1 BS is associated 
genetic defects in the loop of Henle transporters 
affecting sodium, chloride and potassium transport in 
the ascending limb. There is loss of sodium and chloride, 
with resultant volume contraction which instead 
stimulates the rennin-angiotensin II- aldosterone axis. 
Aldosterone promotes sodium uptake and potassium 
excretion, exacerbating hypokalemia. It also stimulates 
hydrogen ion secretion distally (from the distal limb of 
loop of henle) affecting acid base balance in the body 
causing metabolic alkalosis. BS are of five types. It is 
inherited as a autosomal recessive disorder with the 
exception of type V which follows autosomal dominant 
pattern. Types I, II and IV are also called antenatal 
BS because the onset of illness is usually prenatally. 
Children with types I and II usually present to clinicians 
with maternal history of polyhydramnios, prematurity, 
nephrocalcinosis, polyuria, dehydration, and failure to 
thrive. Children with type III, the mildest of all BS, also 
known as classical BS, usually present with salt craving 
habit, low serum magnesium, dehydration and failure 
to thrive. Children with Type IV have clinical features 
similar to that of type I, except that they do not have 
nephrocalcinosis but have sensorineural hearing loss 
instead. The most uncommon BS is of type V, the usual 
clinical features being low parathyroid hormone level, 
hypocalcaemia and hypercalciuria.2 We report a case of 
BS not responding to conventional treatment of growth 
failure. We had also taken written consent from the 
mother for publication of this case report and inclusion 
of the photograph of the child.
CASE REPORT
A 14 months old female child presented with history of 
unable to gain weight since 11 months and recurrent 
episodes of vomiting since 9 months. There was no history 
of consangual marriage, maternal polyhydramnios or 
premature birth. Her dietary intake was of adequate 
calories. There was no constipation.  On examination the 
child looked sick and irritable. There were no obvious 
dysmorphic features. On anthropometry examination, 
head circumference for age was 42 cm, weight for age 
5.5 kg, length for age 69 cm, all of which were below 
-3 Z score. There was no pallor, cyanosis, clubbing, 
icterus or lymphadenopathy. Pulse was 120 beats per 
minute, respiratory rate 36 per minute, temperature 
980 Fahrenheit, blood pressure 95/60 mmHg and 
capillary refill time was below 3 seconds. Examinations 
of cardiovascular, respiratory, gastrointestinal and 
neurological systems were normal. Arterial blood gas 
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examination showed metabolic alkalosis with pH of 
7.56 which was persistently above 7.45 on repeated 
examinations. Likewise urinary chloride was elevated 
(40mEq/L). There was hypokalemia (serum potassium 
2.3 mmol/l), hyponatremia (serum sodium 113 
mmol/L), hypomagnesemia (serum magnesium 1 mg/
dl), normal phosphate level (serum phosphate 3 mg/
dl) and hypercalciuria (urinary calcium: creatinine 
ratio- 0.3).  There was also high urinary excretion of 
sodium (55mEq/L), chloride (59 Eq/L) and potassium 
(44.2mEq/L). Abdominal ultrasonography was suggestive 
of Grade II medico-renal disease without evidence of 
nephrocalcinosis. Results of other investigations such as 
thyroid function test, echocardiography and Computer 
Tomography Scan of the brain were within normal 
limit. Although conformation of diagnosis required 
demonstration of genetic mutation that encode Na+/
K+/2Cl- transporter2, it was not possible in our setting. 
Hence, the diagnosis of Bartter Syndrome Type III was 
made based on clinical findings of multiple episodes 
of vomiting, failure to thrive, normal blood pressure 
and supportive laboratory parameters of hypokalemic 
metabolic alkalosis (chloride resistant- since urinary 
chloride was above 20 mEq/L3), hypercalciuria and 
hypomagnesemia. The child was then treated with 
oral indomethacin (1.5 mg/Kg/day in 3 divided doses) 
along with other supportive management for failure to 
thrive and discharged. When followed up at 1 month 
from discharge, there was significant improvement in 
clinical and laboratory features including weight gain of 
approximately 25g/kg/day. 
Figure 1. Shows  the child before treatment. He was 
thinly built, sunken cheeks, relatively less muscle mass 
and visible ribs with prominent intercostal muscles.
 
Figure 2. Shows the child at 1 month after discharge. 
There is marked improvement in muscle mass, fullness 
of cheeks, decrease in ribs and intercostals muscles 
prominence .
DISCUSSION
BS is a rare inherited defect in the thick ascending limb of 
the loop of henle of nephrons resulting in various tubular 
transport abnormalities of the kidney.4,5 Although, 
patients with classic BS (Type III) may become symptomic 
in the first two years of life, they are usually diagnosed 
at 6 years of age or even later. Similar to children with 
BS of neonatal subtype, patients with classic BS also 
have polyuria, polydipsia, and dehydration; however, 
they have slightly increased urinary excretion of calcium 
without developing renal calculi. They also have marked 
vomiting, dehydration and growth retardation. Although 
hypomagnesemia has also been reported to occur, it is 
typically seen in Gitelman Syndrome.6-8 There is usually 
associated maternal polyhydramnios. Dysmorphic 
features present include triangular facies, protruding 
ears, large eyes and drooping mouth.9 Older children may 
have recurrent episodes of polyuria with dehydration, 
failure to thrive and typical biochemical abnormalities. 
Urinary calcium levels are characteristically elevated.10 
The typical features of hypokalemia, metabolic alkalosis, 
hypercalciuria and normal blood pressure present 
in our case suggest the child to be of BS. Age beyond 
infancy, features of dehydration and presence of low 
serum magnesium suggest it to be of type III. Although 
hypomagnesemia is also seen in Gitelman Syndrome, 
early occurrence of illness in infancy and absence of 
hypocalciuria are against it. Infants of type I or II BS are 
premature and usually have nephrocalcinosis. Absence 
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of sensorineural hearing loss and hypocalcemia also 
decreases possibility of it being type IV or V BS. Hence, 
based on the obvious clinical and laboratory findings, 
our patient was of type III BS. 
Treatment of Bartter Syndrome is directed at 
preventing dehydration, maintaining nutritional status 
and correcting hypokalemia and use of potassium 
sparing diuretics. Magnesium is supplemented for 
hypomagnesemia. Indomethacin, a prostaglandin 
inhibitor, is effective and commonly administered, since 
BS is associated with increase in the renal excretion of 
prostaglandin E2, 11-12 which instead stimulates release 
of aldosterone.13 Therefore, indomethacin would 
help correct hypokalemia by suppressing aldosterone 
release. On receiving definite treatment on time, the 
renal function gets easily corrected, 14 although some 
may go on to develop end-stage renal disease. Since 
the serum potassium level normalized with the use of 
Indomethacin during hospital stay and follow up, we did 
not give further potassium supplements, spironolactone 
or ACE inhibitors.
The diagnosis of Bartter syndrome not only helped the 
child to receive definitive treatment and gain weight 
during follow up but also became good learning curve 
for treating pediatricians to think of a rarer diagnosis 
of failure to thrive in our setup. There have been very 
few reported cases of Bartter Syndrome in the Indian 
subcontinent in past.15 Therefore, our case highlights 
that a high index of suspicion is required to think of BS 
while managing child with failure to thrive specially if 
they are not responding to nutritional correction. In 
addition, simple and low cost treatment of NSAIDs could 
lead to remarkable improvement in the general well 
being of the affected children.
In conclusion, we report a 14 months old female child 
with inability to gain weight and recurrent episodes of 
vomiting with normal blood pressure, failure to thrive, 
normal systemic examination findings, hypokalemic 
metabolic alkalosis, hypercalciuria and hypomagnesemia 
suggesting type III BS. Unusual diagnosis of BS needs to 
be suspected, investigated and treated in all infants with 
failure to thrive including conventional high calories and 
protein diet. 
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